Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Stoke Therapeutics stock

Own Stoke Therapeutics stock in just a few minutes.

Stoke Therapeutics, Inc is a biotechnology business based in the US. Stoke Therapeutics shares (STOK) are listed on the NASDAQ and all prices are listed in US Dollars. Stoke Therapeutics employs 79 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Stoke Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – STOK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Stoke Therapeutics share price

Use our graph to track the performance of STOK stocks over time.

Stoke Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$19.00 - $71.58
50-day moving average $41.36
200-day moving average $49.62
Wall St. target price$68.71
PE ratio 21.6471
Dividend yield N/A (0%)
Earnings per share (TTM) $-11.44

Buy Stoke Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Stoke Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Stoke Therapeutics under- or over-valued?

Valuing Stoke Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Stoke Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Stoke Therapeutics's P/E ratio

Stoke Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Stoke Therapeutics shares trade at around 22x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Stoke Therapeutics financials

Gross profit TTM $0
Return on assets TTM -12.59%
Return on equity TTM -20.47%
Profit margin 0%
Book value $7.14
Market capitalisation $1.2 billion

TTM: trailing 12 months

Shorting Stoke Therapeutics shares

There are currently 3.2 million Stoke Therapeutics shares held short by investors – that's known as Stoke Therapeutics's "short interest". This figure is 10.7% up from 2.9 million last month.

There are a few different ways that this level of interest in shorting Stoke Therapeutics shares can be evaluated.

Stoke Therapeutics's "short interest ratio" (SIR)

Stoke Therapeutics's "short interest ratio" (SIR) is the quantity of Stoke Therapeutics shares currently shorted divided by the average quantity of Stoke Therapeutics shares traded daily (recently around 222765.11627907). Stoke Therapeutics's SIR currently stands at 14.19. In other words for every 100,000 Stoke Therapeutics shares traded daily on the market, roughly 14190 shares are currently held short.

However Stoke Therapeutics's short interest can also be evaluated against the total number of Stoke Therapeutics shares, or, against the total number of tradable Stoke Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Stoke Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Stoke Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.2% of the tradable shares (for every 100,000 tradable Stoke Therapeutics shares, roughly 200 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Stoke Therapeutics.

Find out more about how you can short Stoke Therapeutics stock.

Stoke Therapeutics share dividends

We're not expecting Stoke Therapeutics to pay a dividend over the next 12 months.

Stoke Therapeutics overview

Stoke Therapeutics, Inc. , an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site